First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer.
Ru YanHuali MaLijuan JiangShengjie GuoYanxia ShiXinan ShengYijun ZhangPhilippe E SpiessTingyu LiuTing XueXiaofeng ChenFangjian ZhouXin AnKai YaoFangjian ZhouHui HanPublished in: BJU international (2022)
Anti-PD-1 antibody plus epidermal growth factor receptor blockade and platinum-based chemotherapy showed promising anti-tumour activity, acceptable toxicity, and satisfying long-term survival for stage IV PSCC. Larger clinical trials are needed to validate our findings.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- clinical trial
- locally advanced
- papillary thyroid
- oxidative stress
- squamous cell
- squamous cell carcinoma
- rectal cancer
- small cell lung cancer
- chemotherapy induced
- prostate cancer
- phase ii
- radical prostatectomy
- binding protein
- open label